CART Cell Therapy
Showing 9976 - 10000 of >10,000
Cerebral Palsy, Exercise Therapy Trial (action observation)
Not yet recruiting
- Cerebral Palsy
- Exercise Therapy
- action observation
- (no location specified)
Aug 9, 2023
NSCLC Trial in Baltimore (Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
-
Baltimore, MarylandJohns Hopkins University
Jun 16, 2022
NSCLC Trial in Guangzhou (HA121-28 tablet)
Recruiting
- NSCLC
- HA121-28 tablet
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Centre
Aug 2, 2022
Chronic Kidney Diseases, Obesity, Overweight Trial in Ljubljana (Cognitive Behavioral Therapy (CBT) for managing Obesity)
Recruiting
- Chronic Kidney Diseases
- +2 more
- Cognitive Behavioral Therapy (CBT) for managing Obesity
-
Ljubljana, SloveniaUniversity Medical Centre Ljubljana
Jun 21, 2023
Pelvic Pain, Levator Ani Syndrome, Spastic Pelvic Floor Syndrome Trial in Orlando (SoLá therapy, Pelvic floor physical therapy)
Recruiting
- Pelvic Pain
- +4 more
- SoLá therapy
- Pelvic floor physical therapy
-
Orlando, FloridaOrlando VA Medical Center
Jun 21, 2023
Cerebral Stroke Trial in Fullerton (HandyMotion Treatment Program)
Recruiting
- Cerebral Stroke
- HandyMotion Treatment Program
-
Fullerton, CaliforniaProvidence St. Jude Medical Center
Dec 19, 2022
Randomized Trial for cLBP (Gokhale Project)
Not yet recruiting
- Lower Back Pain Chronic
- Gokhale sensor
- (no location specified)
Dec 12, 2022
Endovascular Treatment Trial in China
Recruiting
- Endovascular Treatment
-
Zhangzhou, Fujian, China
- +5 more
Aug 10, 2023
Pancreatic Cancer, Cancer of the Pancreas Trial in Philadelphia (huCART-meso cells)
Recruiting
- Pancreatic Cancer
- Cancer of the Pancreas
- huCART-meso cells
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Dec 9, 2022
Acute Leukemia in Remission, MDS, Myeloproliferative Syndrome Trial (Fecal Microbiota Transplantation)
Not yet recruiting
- Acute Leukemia in Remission
- +6 more
- Fecal Microbiota Transplantation
-
Amiens, France
- +19 more
Oct 18, 2022
Skin Carcinoma Trial in Duarte (Computer-Assisted Intervention, Dermatoscope, Educational Intervention)
Recruiting
- Skin Carcinoma
- Computer-Assisted Intervention
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 23, 2022
COVID-19 Trial in Jakarta, Bandung (Standard of Care + Quinine Sulfate, Standard of Care)
Recruiting
- COVID-19
- Standard of Care + Quinine Sulfate
- Standard of Care
-
Jakarta, DKI Jakarta, Indonesia
- +1 more
Apr 10, 2023
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)
Not yet recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- XY0206
- Salvage Chemotherapy
- (no location specified)
May 24, 2023
Genetic Determinants of Clindamycin/Rifampin Interaction
Completed
- VA Drug Interaction
-
Paris, FranceGroupe Hospitalier Diaconesses Croix Saint Simon
Oct 24, 2022
Head Neck Cancer Trial in London, Wales (Olaparib, Cisplatin, IMRT)
Active, not recruiting
- Head and Neck Cancer
- Olaparib
- +2 more
-
London, United Kingdom
- +2 more
Nov 1, 2022
Ventilation Heterogeneity Prior to Lung Resection
Enrolling by invitation
- Lung Cancer
- Hyperpolarized 129Xe MRI
- +2 more
-
Hamilton, Ontario, CanadaFirestone Institute for Respiratory Health, Research - St. Josep
Jan 18, 2023
Thoracic Cancer Trial in Shanghai (opioid free anesthesia, Opioid-sparing anesthesia)
Recruiting
- Thoracic Cancer
- opioid free anesthesia
- Opioid-sparing anesthesia
-
Shanghai, China
- +1 more
Apr 26, 2022
Hypertension in Type 2 Diabetics
Recruiting
- Diabetes Mellitus, Type 2
- +2 more
- Blood draw
-
Saint Louis, Missouri
- +1 more
Jul 18, 2022
Dyspareunia, Pelvic Pain, Sexual Dysfunction Trial in Carmel (Pelvic health therapy, Dilator feasability)
Not yet recruiting
- Dyspareunia
- +3 more
- Pelvic health therapy
- Dilator feasability
-
Carmel, IndianaIU Health Schwarz Cancer Center
Oct 3, 2023
To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
Not yet recruiting
- To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
- (no location specified)
Aug 29, 2023